Published in PLoS One on February 12, 2010
Hippo/YAP-mediated rigidity-dependent motor neuron differentiation of human pluripotent stem cells. Nat Mater (2014) 2.09
Guided migration of neural stem cells derived from human embryonic stem cells by an electric field. Stem Cells (2012) 1.11
N,N'-dinitrosopiperazine-mediated ezrin protein phosphorylation via activation of Rho kinase and protein kinase C is involved in metastasis of nasopharyngeal carcinoma 6-10B cells. J Biol Chem (2011) 0.94
14-3-3σ regulates β-catenin-mediated mouse embryonic stem cell proliferation by sequestering GSK-3β. PLoS One (2012) 0.94
Matrix-specified differentiation of human decidua parietalis placental stem cells. Biochem Biophys Res Commun (2013) 0.79
Rho kinase inhibitor Y-27632 promotes the differentiation of human bone marrow mesenchymal stem cells into keratinocyte-like cells in xeno-free conditioned medium. Stem Cell Res Ther (2015) 0.77
Neural crest specification by inhibition of the ROCK/Myosin II pathway. Stem Cells (2015) 0.76
Human pluripotent stem cell (PSC)-derived mesenchymal stem cells (MSCs) show potent neurogenic capacity which is enhanced with cytoskeletal rearrangement. Oncotarget (2016) 0.75
Differentiation patterns of mouse embryonic stem cells and induced pluripotent stem cells into neurons. Cytotechnology (2014) 0.75
Spatio-temporal dependence of the signaling response in immune-receptor trafficking networks regulated by cell density: a theoretical model. PLoS One (2011) 0.75
Wnt signalling in stem cells and cancer. Nature (2005) 19.26
Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell (2004) 16.89
A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol (2007) 13.56
Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med (2003) 12.94
Rho GTPases and their effector proteins. Biochem J (2000) 8.89
Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol (2003) 8.68
Hematopoietic commitment during embryonic stem cell differentiation in culture. Mol Cell Biol (1993) 6.33
Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem (1999) 4.53
The role of the Rho GTPases in neuronal development. Genes Dev (2005) 4.47
WNT signaling pathway and stem cell signaling network. Clin Cancer Res (2007) 4.24
Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem (1996) 3.95
ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett (1996) 3.46
Direct neural fate specification from embryonic stem cells: a primitive mammalian neural stem cell stage acquired through a default mechanism. Neuron (2001) 3.42
Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell (2003) 3.36
Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. J Cell Biol (1998) 2.81
Transcription under the control of nuclear Arm/beta-catenin. Curr Biol (2006) 2.11
Rho-kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin light chain and not ezrin/radixin/moesin proteins at the cleavage furrow. Oncogene (2000) 2.08
Beta-catenin signaling is required for neural differentiation of embryonic stem cells. Development (2004) 1.92
Roles of Rho-associated kinase in cytokinesis; mutations in Rho-associated kinase phosphorylation sites impair cytokinetic segregation of glial filaments. J Cell Biol (1998) 1.69
Roles of Wnt proteins in neural development and maintenance. Curr Opin Neurobiol (2000) 1.68
Keratinocyte differentiation is regulated by the Rho and ROCK signaling pathway. Curr Biol (2003) 1.54
Embryonic stem cells assume a primitive neural stem cell fate in the absence of extrinsic influences. J Cell Biol (2006) 1.54
The Rho-Rock-Myosin signaling axis determines cell-cell integrity of self-renewing pluripotent stem cells. PLoS One (2008) 1.52
RhoA/ROCK regulation of neuritogenesis via profilin IIa-mediated control of actin stability. J Cell Biol (2003) 1.39
Synergistic effects of CoCl(2) and ROCK inhibition on mesenchymal stem cell differentiation into neuron-like cells. J Cell Sci (2006) 1.25
Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis. Stem Cells (2007) 1.17
Fine regulation of RhoA and Rock is required for skeletal muscle differentiation. J Biol Chem (2006) 1.14
ROCK2 and its alternatively spliced isoform ROCK2m positively control the maturation of the myogenic program. Mol Cell Biol (2007) 1.09
Crosstalk between HIF-1 and ROCK pathways in neuronal differentiation of mesenchymal stem cells, neurospheres and in PC12 neurite outgrowth. Mol Cell Neurosci (2007) 1.03
Subcellular localization of beta-catenin is regulated by cell density. Biochem Biophys Res Commun (2002) 1.00
An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med (2006) 4.23
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int (2011) 3.69
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med (2005) 3.00
Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol (2010) 2.32
Ultrafine titanium dioxide particles in the absence of photoactivation can induce oxidative damage to human bronchial epithelial cells. Toxicology (2005) 2.12
Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. J Gastroenterol (2003) 2.09
Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol (2013) 2.06
Isolation of multipotent cells from human term placenta. Stem Cells (2005) 2.03
C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J (2002) 1.99
Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer (2006) 1.92
Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol (2010) 1.88
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood (2009) 1.87
Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res (2005) 1.77
Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance. Am J Pathol (2010) 1.63
Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood (2010) 1.57
Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol (2005) 1.55
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood (2011) 1.55
Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol (2005) 1.54
Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol (2009) 1.46
Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan. J Gastroenterol Hepatol (2010) 1.45
DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood (2011) 1.44
Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-kappaB in chronic hepatitis C. Liver Int (2008) 1.44
Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A (2006) 1.44
Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J Biol Chem (2002) 1.44
Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer (2006) 1.40
Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood (2003) 1.39
Highly efficient cellular labeling of mesoporous nanoparticles in human mesenchymal stem cells: implication for stem cell tracking. FASEB J (2005) 1.37
Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer (2010) 1.34
Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol (2006) 1.32
Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation (2009) 1.30
The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles. Biomaterials (2009) 1.29
Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. J Immunol (2003) 1.28
15d-prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol (2005) 1.28
Quantitative analysis of binding of transcription factor complex to biotinylated DNA probe by a streptavidin-agarose pulldown assay. Anal Biochem (2003) 1.27
FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. J Gastroenterol (2009) 1.27
The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood (2012) 1.25
Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics (2006) 1.25
Development of a polymerase chain reaction procedure for detection and differentiation of duck and goose circovirus. Avian Dis (2006) 1.24
Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer (2011) 1.22
Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection. J Exp Med (2007) 1.21
Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon. Cancer Res (2007) 1.21
The inhibitory effect of superparamagnetic iron oxide nanoparticle (Ferucarbotran) on osteogenic differentiation and its signaling mechanism in human mesenchymal stem cells. Toxicol Appl Pharmacol (2010) 1.19
Serum levels of interleukin-10 and interleukin-12 predict early, spontaneous hepatitis B virus e antigen seroconversion. Gastroenterology (2009) 1.19
Insulin resistance is associated with hepatocellular carcinoma in chronic hepatitis C infection. World J Gastroenterol (2010) 1.19
Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins. J Biol Chem (2001) 1.17
Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis. Stem Cells (2007) 1.17
Differential receptor binding affinities of influenza hemagglutinins on glycan arrays. J Am Chem Soc (2010) 1.16
Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Mol Cancer Res (2010) 1.15
Transient elastography and simple blood markers in the diagnosis of esophageal varices for compensated patients with hepatitis B virus-related cirrhosis. J Gastroenterol Hepatol (2012) 1.14
Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. J Surg Oncol (2008) 1.13
Liver resection improves the survival of patients with multiple hepatocellular carcinomas. Ann Surg Oncol (2009) 1.11
Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood (2006) 1.10
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. Am J Hematol (2013) 1.10
Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res (2005) 1.10
Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood (2011) 1.10
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma. Hum Pathol (2009) 1.08
The variable number of tandem repeat polymorphism of platelet glycoprotein Ibalpha and risk of coronary heart disease. Blood (2003) 1.08
Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins. J Cell Physiol (2009) 1.07
Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int (2005) 1.06
Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation (2004) 1.05
Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study. Arterioscler Thromb Vasc Biol (2002) 1.05
Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Circulation (2002) 1.04
Pedunculated hepatic hemangioma: report of two cases. J Formos Med Assoc (2002) 1.04
Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine (2004) 1.03
Reactive oxygen species are involved in arsenic trioxide inhibition of pyruvate dehydrogenase activity. Chem Res Toxicol (2003) 1.03
Natural course of hepatic focal nodular hyperplasia: a long-term follow-up study with sonography. J Clin Ultrasound (2009) 1.02
Nestin is essential for zebrafish brain and eye development through control of progenitor cell apoptosis. PLoS One (2010) 1.02
Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. Oncol Rep (2007) 1.01
A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother (2012) 1.01
Overexpression of 14-3-3ε predicts tumour metastasis and poor survival in hepatocellular carcinoma. Histopathology (2011) 1.01
Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation (2002) 1.00
14-3-3ε overexpression contributes to epithelial-mesenchymal transition of hepatocellular carcinoma. PLoS One (2013) 1.00
Diaqua-bis(2,5-di-4-pyridyl-1,3,4-thia-diazole-κN)bis-(thio-cyanato-κN)copper(II) dihydrate. Acta Crystallogr Sect E Struct Rep Online (2008) 1.00
Transcriptional Control of COX-2 via C/EBPbeta. Arterioscler Thromb Vasc Biol (2005) 0.99
Downregulation of Sirt1 as aging change in advanced heart failure. J Biomed Sci (2014) 0.99
Is delayed normalization of alanine aminotransferase a poor prognostic predictor in chronic hepatitis C patients treated with a combined interferon and ribavirin therapy? J Gastroenterol Hepatol (2002) 0.99
Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma. Int J Cancer (2007) 0.98
TLR 2 induces vascular smooth muscle cell migration through cAMP response element-binding protein-mediated interleukin-6 production. Arterioscler Thromb Vasc Biol (2012) 0.98
Cellular and molecular biology of prostacyclin synthase. Biochem Biophys Res Commun (2005) 0.98
Contrast-enhanced ultrasonographic spoke-wheel sign in hepatic focal nodular hyperplasia. Eur J Radiol (2006) 0.98
Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing peroxisome proliferator-activated receptor-delta transcriptional pathway. Mol Pharmacol (2008) 0.98
BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. Sci Signal (2013) 0.97
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am J Hematol (2013) 0.97
Electrophysiological signal analysis and visualization using Cloudwave for epilepsy clinical research. Stud Health Technol Inform (2013) 0.97
Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. J Gastroenterol Hepatol (2005) 0.96
Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis (2007) 0.96
A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. J Antimicrob Chemother (2011) 0.96
Association of inflammatory and anti-inflammatory cytokines with insulin resistance in chronic hepatitis C. Liver Int (2009) 0.96
Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance. Exp Cell Res (2005) 0.96
Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig Dis Sci (2006) 0.96
P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study. Atherosclerosis (2005) 0.95
Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Trans R Soc Trop Med Hyg (2006) 0.95